September 15, 2017Open Access

Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis

Key Points

Key points are not available for this paper at this time.

Abstract

Combination therapy of colistin with sulbactam demonstrates superiority in terms of microbiological cure with a safety profile similar to that of colistin monotherapy. Thus, our findings support the use of this combination as a treatment for MDR- and XDR-AB infections.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Kengkla et al. (Fri,) studied this question.

synapsesocial.com/papers/69d8342bf4e559c61eae2d48 https://doi.org/https://doi.org/10.1093/jac/dkx368

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Treatment of Multidrug‐Resistant<i>Acinetobacter baumannii</i>Ventilator‐Associated Pneumonia (VAP) with Intravenous Colistin: A Comparison with Imipenem‐Susceptible VAP2003 · 470 citations
2Pharmacokinetic and pharmacodynamic evaluation of tigecycline2011 · 75 citations
3Measuring inconsistency in meta-analyses2003 · 62,650 citations
4Meta-analysis of colistin for the treatment of Acinetobacter baumannii infection2015 · 62 citations
5Efficacy and Safety of Polymyxins for the Treatment of Acinectobacter baumannii Infection: A Systematic Review and Meta-Analysis2014 · 48 citations

Bookmark

View Full Paper